All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Completed, but no date Terminated||2012-005352-41||A phase II randomized, open-label study evaluating the addition of trastuzumab to (nabTM)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with HER2 positi...||bad-data|
|Ongoing||2013-001226-25||A phase II randomized, open-label neo-adjuvant study of standard chemotherapy regimen compared to high dose chemotherapy regimen with autologous stem cell transplantation in patients with triple negat...||not-yet-due|
|Ongoing||2014-003039-20||RANDOMIZED PHASE II STUDY WITH SEQUENTIAL NON-CROSS RESISTANT CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED INOPERABLE OR METASTATIC GASTRO-ESOPHAGEAL ADENOCARCINOMA STUDIO RANDOMIZZATO DI FASE II...||not-yet-due|
|Ongoing||2015-000298-11||A phase II, open label, controlled study of olaparib in locally advanced ER, PgR and HER2 negative (Triple Negative) and in locally advanced germline BRCA mutation-positive breast cancer patients: bio...||not-yet-due|